We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · January 18, 2017

Efficacy and Safety of Guselkumab vs Adalimumab for Continuous Treatment of Moderate to Severe Psoriasis

Journal of the American Academy of Dermatology


Additional Info

Journal of the American Academy of Dermatology
Efficacy and Safety of Guselkumab, an Anti-Interleukin-23 Monoclonal Antibody, Compared With Adalimumab for the Continuous Treatment of Patients With Moderate to Severe Psoriasis: Results From the Phase III, Double-Blinded, Placebo- and Active Comparator-Controlled VOYAGE 1 Trial
J Am Acad Dermatol 2016 Dec 29;[EPub Ahead of Print], A Blauvelt, KA Papp, CE Griffiths, B Randazzo, Y Wasfi, YK Shen, S Li, AB Kimball

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading